Liposome-based drug delivery in breast cancer treatment

被引：77

作者：

Park J.W. ^{[1
]}

机构：

[1] UCSF Comprehensive Cancer Center, San Francisco, CA 94115-1710

来源：

Breast Cancer Research | / 4卷 / 3期

关键词：

Drug delivery; Immunoliposomes; Liposomes; Monoclonal antibody; Polymers;

D O I：

10.1186/bcr432

中图分类号：

学科分类号：

摘要：

Drug delivery systems can in principle provide enhanced efficacy and/or reduced toxicity for anticancer agents. Long circulating macromolecular carriers such as liposomes can exploit the 'enhanced permeability and retention' effect for preferential extravasation from tumor vessels. Liposomal anthracyclines have achieved highly efficient drug encapsulation, resulting in significant anticancer activity with reduced cardiotoxicity, and include versions with greatly prolonged circulation such as liposomal daunorubicin and pegylated liposomal doxorubicin. Pegylated liposomal doxorubucin has shown substantial efficacy in breast cancer treatment both as monotherapy and in combination with other chemotherapeutics. Additional liposome constructs are being developed for the delivery of other drugs. The next generation of delivery systems will include true molecular targeting; immunoliposomes and other ligand-directed constructs represent an integration of biological components capable of tumor recognition with delivery technologies.

引用

页码：95 / 99

页数：4

共 25 条

[1]

Matsumura Y., Maeda H., A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS, Cancer Res, 6, pp. 193-210, (1986)

[2]

Batist G., Ramakrishnan G., Rao C.S., Chandrasekharan A., Gutheil J., Guthrie T., Shah P., Khojasteh A., Nair M.K., Hoelzer K., Tkaczuk K., Park Y.C., Lee L.W., Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, cancer, J. Clin. Oncol, 19, pp. 1444-1454, (2001)

[3]

Williams G., Cortazar P., Pazdur R., Developing drugs to decrease the toxicity of chemotherapy, J. Clin. Oncol, 19, pp. 3439-3441, (2001)

[4]

Gill P.S., Wernz J., Scadden D.T., Cohen P., Mukwaya G.M., von Roenn J.H., Jacobs M., Kempin S., Silverberg I., Gonzales G., Rarick M.U., Myers A.M., Shepherd F., Sawka C., Pike M.C., Ross M.E., Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma, J. Clin. Oncol, 14, pp. 2353-2364, (1996)

[5]

Northfelt D.W., Martin F.J., Working P., Volberding P.A., Russell J., Newman M., Amantea M.A., Kaplan L.D., Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma, J. Clin. Pharmacol, 36, pp. 55-63, (1996)

[6]

Symon Z., Peyser A., Tzemach D., Lyass O., Sucher E., Shezen E., Gabizon A., Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes, Cancer, 86, pp. 72-78, (1999)

[7]

Ranson M.R., Carmichael J., O'Byrne K., Stewart S., Smith D., Howell A., Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial, J. Clin. Oncol, 15, pp. 3185-3191, (1997)

[8]

Silverman P., Overmoyer B., Holder L., Tripathy D., Marrs N., Sharpington T., Doxil and intravenous cyclophosphamide as first line therapy for patients with metastatic breast cancer (MBC): Interim results of an ongoing pilot trial, Proc. Am. Soc. Clin. Oncol, 18, (1999)

[9]

Rivera E., Valero V., Syrewicz L., Rahman Z., Esteva F.L., Theriault R.L., Rosales M.M., Booser D., Murray J.L., Bast R.C. Jr., Hortobagyi G.N., Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer, J. Clin. Oncol, 19, pp. 1716-1722, (2001)

[10]

Sparano J.A., Malik U., Rajdev L., Sarta C., Hopkins U., Wolff A.C., Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer, J. Clin. Oncol, 19, pp. 3117-3125, (2001)

← 1 2 3 →